The final trading day of 2013 closed at a record high for the Dow with the blue chip index climbing 72 points to 16,576. Nasdaq gained 22 points to 4176.
On the upside
Immunomedics (Nasdaq: IMMU) received a patent for conjugating SN-38.
A Seeking Alpha contributor wrote that CytRx (Nasdaq: CYTR) was poised to climb.
Zacks noted that Hecla Mining (NYSE: HL) would be a great investment.
On the downside
Investors locked in profits on Biolase (Nasdaq: BIOL).
Profit taking weighed down shares of Corporate Office Properties Trust (NYSE: OFC).
Investors locked in profits on Amyris (Nasdaq: AMRS).
In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 gained 7 points to 1848.